Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Celgene Corporation
- 29 Jul 2015 Status changed from active, no longer recruiting to completed ClinicalTrials.gov record.
- 02 May 2013 Planned End Date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov record.
- 02 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.